Investigation Report on China Risedronate Sodium Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||333639|
|出版日期||內容資訊||英文 30 Pages
|Risedronate Sodium的中國市場分析 Investigation Report on China Risedronate Sodium Market, 2010-2019|
|出版日期: 2015年06月25日||內容資訊: 英文 30 Pages||
在中國隨著人口高齡化，骨質疏鬆症的患者增加，患者數變多，次於心血管疾病。根據統計調查，中國的全國人民的12.4％，50歲以上的女性50％患骨質疏鬆症。Risedronate Sodium是以停經後女性為對象的骨質疏鬆症的預防藥，2004年的階段全球整體達成10億美元以上的銷售額。中國國內的銷售額 (調查樣品醫院的情況) ，從2008年的4萬人民幣以下，2014年達971萬人民幣，以年複合成長率(CAGR)156％達成飛躍性成長。
With the ageing population, China has become the country with the largest number of people suffering from osteoporosis which is the most severe disease second to cardiovascular diseases. A nationwide large-scale epidemiological survey has also shown that the incidence of osteoporosis in China is 12.4% and that this figure among women aged 50 and above is 50%. It is estimated that the number of osteoporosis patients and patients with low bone mass will rise to 280 million by 2020.
Currently, drugs for the prevention and treatment of osteoporosis are mainly categorized into bone resorption inhibitor which includes diphosphonate (alendronate, etidronate and risedronate), sex hormone, calcitonin, selective estrogen receptor modulator and bone formation promoter, fluoride product, vitamin D and calcium preparation, parathyroid hormone included.
As a member of the new generation of osteoporosis drugs, risedronate sodium is used for the treatment and prevention of osteoporosis in postmenopausal women. Risedronate sodium has brought in a large amount of sales value in the global market, for example, over USD 1 billion in 2004. According to CRI's market survey, risedronate sodium develops fast after appearing in the Chinese market, annual sales value in sample hospitals rising from less than 40,000 in 2008 to CNY 9.71 million in 2014 and CAGR during this period reaching 156%. Risedronate sodiums in the Chinese market are all produced by local enterprises represented by Kunming Jida Pharmaceutical Co., Ltd, Topfond, Yangtze River Pharmaceutical Group, Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd and Beijing SL Pharm, among which Kunming Jida Pharmaceutical Co., Ltd has the largest market share of 84% for sales value in 2014.
With the ageing population, the incidence of osteoporosis will continue to grow. Therefore the market size of risedronate sodium is expected to keep expanding fast in the next few years in China.
Readers can get at least the following information from this report:
The author suggests the following groups of people purchase this report: